Amendment to Series A Common Stock Purchase Warrant between NeuroBo Pharmaceuticals, Inc. and Dong-A ST. Co. Ltd.

Summary

This amendment, effective April 12, 2023, modifies the Series A Common Stock Purchase Warrant originally issued by NeuroBo Pharmaceuticals, Inc. to Dong-A ST. Co. Ltd. on November 8, 2022. The amendment removes all exercise limitations previously set out in Section 2(e) of the warrant, including any related definitions or provisions. All other terms of the original warrant remain unchanged and in effect.

EX-4.1 2 nrbo-20230412xex4d1.htm EX-4.1

Exhibit 4.1

AMENDMENT TO THE

SERIES A COMMON STOCK PURCHASE WARRANT

ISSUED TO DONG-A ST. CO. LTD. BY

NEUROBO PHARMACEUTICALS, INC.

The Series A Common Stock Purchase Warrant dated November 8, 2022 (the “Series A Warrant”) is hereby amended as follows, effective as of April 12, 2023.

1.Section 2(e) (Holder’s Exercise Limitations) is hereby deleted in its entirety, and all references to “Beneficial Ownership Limitation”, ‘Attribution Parties” and any other provision or definition therein providing for or relating to the exercise limitations in Section 2(e) are hereby deemed removed and without further force or effect.

2.Except as specifically amended herein, the Series A Warrant shall remain unchanged and in full force and effect.

NEUROBO PHARMACEUTICALS, INC.

By:	/s/ Joseph Hooker
	Name:	Joseph Hooker
	Title:	Interim CEO and President